Form 4: Supernus Pharmaceuticals SVP Jonathan Rubin Reports Stock Transactions

Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock related to performance share units.

Summary

• On December 27, 2024, Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, executed transactions involving Supernus Pharmaceuticals common stock.
• Rubin acquired 750 shares of common stock upon the settlement of performance share units granted on February 23, 2023.
• He also acquired 1,875 shares of common stock upon the settlement of performance share units granted on February 22, 2024.
• Additionally, Rubin disposed of 281 shares and 821 shares of common stock to satisfy tax withholding requirements related to the vesting of performance share units, at a price of $35.59 per share.
• Following these transactions, Rubin directly owns 6,595 shares of Supernus Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions related to executive compensation.

Positives

• The vesting of performance share units indicates the achievement of certain performance objectives by the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates